Clinical Trial Update: CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial results for CMC-544 in relapsed/refractory acute lymphoblastic leukemia (ALL) completed, with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• CMC-544

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Lymphoblastic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2019-05-22